Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis

Medicine & Life Sciences

• Congenital Myasthenic Syndromes 100%
• Neuromuscular Junction 73%
• Myasthenia Gravis 73%
• Collagen 48%
• Acetylcholinesterase 32%
• Cholinergic Receptors 13%
• Immunoglobulin G 12%
• Muscle Weakness 8%
• Endplate Acetylcholinesterase Deficiency 8%
• perlecan 6%
• Heparan Sulfate Proteoglycans 5%
• Dependovirus 5%
• Muscles 5%
• Forelimb 5%
• Cholinesterase Inhibitors 4%
• Symptom Flare Up 4%
• Receptor Protein-Tyrosine Kinases 4%
• Transgenes 4%
• Basement Membrane 4%
• Intravenous Administration 3%
• Synaptic Transmission 3%
• Serogroup 3%
• Cluster Analysis 3%
• In Vitro Techniques 3%
• Extremities 3%
• Injections 2%
• Antibodies 2%
• Proteins 1%

Chemical Compounds

• Neuromuscular 88%
• Collagen 59%
• Acetylcholine 14%
• Heparan Sulfate Proteoglycan 6%
• Block Like Crystal 6%
• Cholinesterase Inhibitor 5%
• Tyrosine 4%
• Protein 1%